Publicaciones en colaboración con investigadores/as de University of Melbourne (71)

2024

  1. Acute kidney disease beyond day 7 after major surgery: a secondary analysis of the EPIS-AKI trial

    Intensive Care Medicine, Vol. 50, Núm. 2, pp. 247-257

  2. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

    Haematologica, Vol. 109, Núm. 7, pp. 2239-2249

  3. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study

    HemaSphere

  4. Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

    Frontiers in Oncology, Vol. 14

  5. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

  6. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

    Ophthalmology, Vol. 131, Núm. 8, pp. 914-926

  7. Technical considerations for isolated limb perfusion: A consensus paper

    European Journal of Surgical Oncology, Vol. 50, Núm. 6

2023

  1. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  2. Contemporary medical, device, and surgical therapies for obesity in adults

    The Lancet, Vol. 401, Núm. 10382, pp. 1116-1130

  3. Epidemiology of surgery associated acute kidney injury (EPIS-AKI): a prospective international observational multi-center clinical study

    Intensive Care Medicine, Vol. 49, Núm. 12, pp. 1441-1455

  4. Mechanical Thrombectomy Global Access for Stroke (MT-GLASS): A Mission Thrombectomy (MT-2020 Plus) Study

    Circulation, Vol. 147, Núm. 16, pp. 1208-1220

  5. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908

    Neuro-Oncology, Vol. 25, Núm. 8, pp. 1530-1545

  6. Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation Sparing Approaches: An International Cohort Study

    Journal of Clinical Oncology, Vol. 41, Núm. 10, pp. 1921-1932

2022

  1. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293

  2. Consensus Statement on Bone Conduction Devices and Active Middle Ear Implants in Conductive and Mixed Hearing Loss

    Otology and Neurotology, Vol. 43, Núm. 5, pp. 513-529

  3. Consensus-Based Technical Recommendations for Clinical Translation of Renal Phase Contrast MRI

    Journal of Magnetic Resonance Imaging, Vol. 55, Núm. 2, pp. 323-335

  4. Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110] (Clinical Lymphoma, Myeloma and Leukemia (2021) 21(S2) (S1–S189), (S2152265021X00122))

    Clinical Lymphoma, Myeloma and Leukemia

  5. Evaluation of a Transimpedance Matrix Algorithm to Detect Anomalous Cochlear Implant Electrode Position

    Audiology and Neurotology, Vol. 27, Núm. 5, pp. 347-355

  6. IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S387

  7. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

    The Lancet Oncology, Vol. 23, Núm. 3, pp. 416-427